Hyperuricemia and Progression of Chronic Kidney Disease : A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy
The relationship between hyperuricemia, gout, and renal disease has been investigated for several years. From the beginning, kidney disease has been considered a complication of gout; however, the viewpoints changed, claiming that hypertension and elevated uric acid (UA) levels are caused by decreased urate excretion in patients with renal impairment. To date, several examples of evidence support the role of hyperuricemia in cardiovascular or renal diseases. Several mechanisms have been identified that explain the relationship between hyperuricemia and chronic kidney disease, including the crystal effect, renin-angiotensin-aldosterone system activation, nitric oxide synthesis inhibition, and intracellular oxidative stress stimulation, and urate-lowering therapy (ULT) has been proven to reduce renal disease progression in the past few years. In this comprehensive review, the source and physiology of UA are introduced, and the mechanisms that explain the reciprocal relationship between hyperuricemia and kidney disease are reviewed. Lastly, current evidence supporting the use of ULT to postpone renal disease progression in patients with hyperuricemia and gout are summarized.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Diagnostics (Basel, Switzerland) - 11(2021), 9 vom: 13. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Tao Han [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allopurinol |
|---|
| Anmerkungen: |
Date Revised 01.10.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/diagnostics11091674 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331156253 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331156253 | ||
| 003 | DE-627 | ||
| 005 | 20231225212835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/diagnostics11091674 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1103.xml |
| 035 | |a (DE-627)NLM331156253 | ||
| 035 | |a (NLM)34574015 | ||
| 035 | |a (PII)1674 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Tao Han |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hyperuricemia and Progression of Chronic Kidney Disease |b A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.10.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The relationship between hyperuricemia, gout, and renal disease has been investigated for several years. From the beginning, kidney disease has been considered a complication of gout; however, the viewpoints changed, claiming that hypertension and elevated uric acid (UA) levels are caused by decreased urate excretion in patients with renal impairment. To date, several examples of evidence support the role of hyperuricemia in cardiovascular or renal diseases. Several mechanisms have been identified that explain the relationship between hyperuricemia and chronic kidney disease, including the crystal effect, renin-angiotensin-aldosterone system activation, nitric oxide synthesis inhibition, and intracellular oxidative stress stimulation, and urate-lowering therapy (ULT) has been proven to reduce renal disease progression in the past few years. In this comprehensive review, the source and physiology of UA are introduced, and the mechanisms that explain the reciprocal relationship between hyperuricemia and kidney disease are reviewed. Lastly, current evidence supporting the use of ULT to postpone renal disease progression in patients with hyperuricemia and gout are summarized | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a allopurinol | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a febuxostat | |
| 650 | 4 | |a gout | |
| 650 | 4 | |a hyperuricemia | |
| 650 | 4 | |a xanthine oxidase inhibitor | |
| 700 | 1 | |a Chen, Jia-Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Chao-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Chih-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Huang-Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnostics (Basel, Switzerland) |d 2011 |g 11(2021), 9 vom: 13. Sept. |w (DE-627)NLM250111136 |x 2075-4418 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:9 |g day:13 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/diagnostics11091674 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 9 |b 13 |c 09 | ||